Samsung Biologics

207940.KO

681.55 USD

-1.07

-0.16%

Overview

Last close

681.55 usd

Market cap

48.51B usd

52 week high

761.21 usd

52 week low

521.20 usd

Target price

680.33 usd

Valuation

P/E

N/A

Forward P/E

58.8235

Price/Sales

16.4188

Price/Book Value

6.8467

Enterprise Value

50.90B usd

EV/Revenue

16.4529

EV/EBITDA

37.0523

Key financials

Revenue TTM

3.09B usd

Gross Profit TTM

1.55B usd

EBITDA TTM

1.31B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

11.76B usd

Net debt

643.53M usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.